Shares of Mirati Therapeutics Inc. (NASDAQ:MRTX) have received an average recommendation of “Buy” from the ten research firms that are presently covering the firm. Four investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $22.77.
Several equities research analysts have recently issued reports on the stock. Wedbush reissued an “outperform” rating and set a $12.00 price objective on shares of Mirati Therapeutics in a research report on Tuesday, October 4th. Piper Jaffray Cos. set a $7.00 price objective on shares of Mirati Therapeutics and gave the stock a “hold” rating in a research report on Thursday, August 18th. Finally, Zacks Investment Research raised shares of Mirati Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 6th.
Several hedge funds and other institutional investors have recently made changes to their positions in MRTX. Aviva Holdings Ltd. increased its position in shares of Mirati Therapeutics by 28.9% in the second quarter. Aviva Holdings Ltd. now owns 1,992,085 shares of the company’s stock worth $10,877,000 after buying an additional 446,084 shares during the period. venBio Select Advisor LLC increased its position in shares of Mirati Therapeutics by 11.6% in the first quarter. venBio Select Advisor LLC now owns 1,404,055 shares of the company’s stock worth $30,047,000 after buying an additional 146,000 shares during the period. Vanguard Group Inc. increased its position in shares of Mirati Therapeutics by 12.2% in the second quarter. Vanguard Group Inc. now owns 624,044 shares of the company’s stock worth $3,407,000 after buying an additional 67,729 shares during the period. BlackRock Fund Advisors increased its position in shares of Mirati Therapeutics by 10.1% in the second quarter. BlackRock Fund Advisors now owns 331,008 shares of the company’s stock worth $1,807,000 after buying an additional 30,400 shares during the period. Finally, Macquarie Group Ltd. purchased a new position in shares of Mirati Therapeutics during the second quarter worth approximately $437,000. 69.40% of the stock is owned by institutional investors.
Mirati Therapeutics (NASDAQ:MRTX) opened at 5.24 on Friday. The firm’s market cap is $104.40 million. The stock’s 50 day moving average is $5.57 and its 200-day moving average is $10.51. Mirati Therapeutics has a 12 month low of $4.40 and a 12 month high of $43.20.
Mirati Therapeutics (NASDAQ:MRTX) last issued its quarterly earnings data on Thursday, August 4th. The company reported ($1.11) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.15) by $0.04. On average, analysts anticipate that Mirati Therapeutics will post ($4.45) earnings per share for the current fiscal year.
About Mirati Therapeutics
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.